A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII. (Q40324434)

19 September 2017

title

A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII. (English)

1 reference

19 September 2017

0 references

9

Sebastian Ulbert

1 reference

19 September 2017

2

Stefan Chabierski

1 reference

19 September 2017

Anne Schneeweiss

1

1 reference

19 September 2017

Mathias Salomo

3

1 reference

19 September 2017

Nicolas Delaroque

4

1 reference

19 September 2017

Samiya Al-Robaiy

5

1 reference

19 September 2017

Thomas Grunwald

6

1 reference

19 September 2017

Kurt Bürki

7

1 reference

19 September 2017

Uwe G Liebert

8

1 reference

19 September 2017

language of work or name

English

0 references

publication date

17 May 2011

1 reference

19 September 2017

1 reference

19 September 2017

volume

29

1 reference

19 September 2017

issue

37

1 reference

19 September 2017

page(s)

6352-6357

1 reference

Virology, pathology, and clinical manifestations of West Nile virus disease

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.116

West Nile virus and its emergence in the United States of America

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.116

The host immunologic response to West Nile encephalitis virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.116

West Nile virus: the complex biology of an emerging pathogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.116

A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.116

A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.116

Immunization with West Nile virus envelope domain III protects mice against lethal infection with homologous and heterologous virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.116

Immunogenicity and Protective Efficacy of a Recombinant Subunit West Nile Virus Vaccine in Rhesus Monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.116

DNA vaccines: ready for prime time?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.116

West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.116

West Nile premembrane-envelope genetic vaccine encoded as a chimera containing the transmembrane and cytoplasmic domains of a lysosome-associated membrane protein: increased cellular concentration of the transgene product, targeting to the MHC II co

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.116

Co-immunization with West Nile DNA and inactivated vaccines provides synergistic increases in their immunogenicities in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.116

Immune response to synthetic peptides of dengue prM protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.116

Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.116

Induction of Epitope-Specific Neutralizing Antibodies against West Nile Virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.116

Protective efficacy of a plasmid DNA encoding Japanese encephalitis virus envelope protein fused to tissue plasminogen activator signal sequences: studies in a murine intracerebral virus challenge model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.116

Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.116

Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.116

Structural basis of West Nile virus neutralization by a therapeutic antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.116

The memory T cell response to West Nile virus in symptomatic humans following natural infection is not influenced by age and is dominated by a restricted set of CD8+ T cell epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.116

Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.116

A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.116

Coimmunization with an optimized IL15 plasmid adjuvant enhances humoral immunity via stimulating B cells induced by genetically engineered DNA vaccines expressing consensus JEV and WNV E DIII.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.116

Heterologous prime-boost vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.116

10.1016/J.VACCINE.2011.04.116

7 January 2021

Identifiers

DOI

1 reference

19 September 2017

1 reference